Dry and Wet Age-Related Macular Degeneration – Unmet Need – Unmet Need – Wet Age-Related Macular Degeneration (US/EU)
Wet AMD (age-related macular degeneration) is a leading cause of vision loss among older adults, with significant implications on patient’s independence and quality of life. The treatment landscape is dominated by intravitreal therapies such as Eylea, Eylea HD, and Vabysmo, which have established strong patient share in both the United States and EU5. Despite these options, unmet needs persist, particularly around reducing treatment burden, sustained vision benefits, and addressing variability in patient response. The late-phase pipeline is active, with emerging long-term treatment options such as gene therapies (i.e., AbbVie / Regenxbio’s sura-vec, Adverum / Eli Lilly’s ixo-vec, and 4DMT / Otsuka’s 4D-150) and resorbable intravitreal implant formulations of tyrosine kinase inhibitors (e.g., EyePoint’s Duravyu, Ocular Therapeutix’s Axpaxli) aiming to reshape market dynamics. As competition intensifies, understanding ophthalmologists’ prescribing behaviors and the evolving expectations for convenience and efficacy will be critical for strategic positioning in this dynamic market.
Questions answered
- How do wet AMD therapies perform on key clinical attributes?
- What are the prevailing areas of unmet need in wet AMD treatment?
- What trade-offs are surveyed ophthalmologists willing to make across key clinical attributes and price for a new therapy for wet AMD?
- What factors will drive adoption of novel therapies in this competitive landscape?
Geography: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 31 European ophthalmologists
Key drugs covered: Eylea, Eylea HD, Vabysmo
Product description
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
Key feature: The Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
